AbbVie launching ovarian cancer therapy Elahere in UK at US list price

Core Insights - AbbVie announced that its ovarian cancer treatment Elahere will have the same list price in the UK as it does in the US [2] Pricing Strategy - The wholesale acquisition cost of Elahere (mirvetuximab soravtansine) will be consistent across both the UK and US markets [2]